Search Results

Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present at the Oxford Global Immuno US 2023, to be held on October 12-13, 2023 in San Diego, CA.

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing newer iterations that will take cancer care to the next level.

Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies in oncology that address cancer immune resistance, announced today financial results for the three months ended March 31, 2024 and provided a corporate update.

Kineta, Inc. announced today that the Company will be attending and presenting at the following upcoming investors conferences.

[20-June-2024] KAN-003 seeks to improve outcomes for patients with ICI-naive cancers and is undergoing preclinical studies in collaboration with the MD Anderson Cancer Center. PRINCETON, N.J. , June 20, 2024 /PRNewswire/ -- Kanvas Biosciences , a full-stack spatial biology company, today introduced its newest drug candidate in its Immuno-oncology Program: KAN-003. The Kanvas platform

Kineta, Inc. (Nasdaq: KA) announced today that two abstracts have been accepted for poster presentation on Kineta’s immuno-oncology therapies at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held November 1-5, 2023, in San Diego, California and virtually.